Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990;80(3):213-23.
doi: 10.1007/BF01245123.

Oxaprotiline enantiomers given repeatedly and brain alpha-adrenoceptors

Affiliations

Oxaprotiline enantiomers given repeatedly and brain alpha-adrenoceptors

J Maj et al. J Neural Transm Gen Sect. 1990.

Abstract

The influence of (+)- and (-)-oxaprotiline (OXA) given repeatedly on the behavioural effects mediated by alpha 1- and alpha 2-adrenoceptors as well as on the binding to brain alpha 1-adrenoceptors was studied. (+)-OXA given repeatedly for 14 days (but not 3 or 7 days) enhanced exploratory hyperactivity of rats induced by methoxamine injected intracerebroventricularly; (-)-OXA given for 3, but not 7 or 14 days, increased the methoxamine-induced exploration in rats. The locomotor hyperactivity induced in mice by d,1-threo-3,4-dihydroxyphenylserine was increased by repeated (14 days) (-)-OXA but not (+)-OXA. Neither OXA enantiomers given repeatedly modified the clonidine-induced locomotor hypoactivity in mice. Both enantiomers given repeatedly did not change the binding of [3H] prazosin to alpha 1-adrenoceptors (Bmax, KD) in the thalamus and hippocampus. Repeated (+)-OXA increased the affinity of alpha 1-adrenoceptors for phenylephrine in the cortex, thalamus and hippocampus. A similar effect of (-)-OXA was observed in the hippocampus only. The results indicate that both OXA enantiomers are able to enhance the responsiveness of brain alpha 1-adrenergic system, probably via the increase in the affinity of alpha 1-adrenoceptors for their agonists.

PubMed Disclaimer

References

    1. Psychopharmacology (Berl). 1985;87(1):116-8 - PubMed
    1. Arch Int Pharmacodyn Ther. 1979 Nov;242(1):59-76 - PubMed
    1. J Pharm Pharmacol. 1983 Mar;35(3):180-1 - PubMed
    1. Neurochem Int. 1983;5(5):649-59 - PubMed
    1. Psychopharmacology (Berl). 1986;88(2):240-6 - PubMed